Drug Trial Radar · NCT05394519
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,200
Actual
Start
Feb 1, 2023
Primary completion
Jan 28, 2025
Study completion Feb 3, 2025
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- May 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
Conditions
- Overweight
- Obesity
- Type 2 Diabetes Mellitus
Interventions
CagrilintideDrug
Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
SemaglutideDrug
Semaglutide administered subcutaneously (s.c., under the skin) once-weekly
Placebo cagrilintideDrug
Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
Placebo semaglutideDrug
Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 68)
- Achievement of greater than or equal to (≥) 5% weight reductionTime frame: From baseline (week 0) to end of treatment (week 68)
Locations
179 sites in 13 countries. Site status is shown where the registry gives one.
John Muir Physicians Network
Concord, California
Headlands Research California, LLC
Escondido, California
Providence Medical Foundation
Fullerton, California
St. Jos Heritage Hlthcr_Fllrtn
Fullerton, California
Diabetes/Lipid Mgmt & Res Ctr
Huntington Beach, California
Clinical Trials Research
Lincoln, California
Velocity Clin Res Los Angeles
Los Angeles, California
Velocity Clin Res Wstlke
Los Angeles, California
Desert Oasis Hlthcr Med Group
Palm Springs, California
Diablo Clinical Research, Inc.
Walnut Creek, California
New West Physicians,Inc.
Golden, Colorado
Clinical Res Of W Florida Inc
Clearwater, Florida
Northeast Research Institute
Fleming Island, Florida
Jacksonville Ctr For Clin Res
Jacksonville, Florida
Renstar Medical Research
Ocala, Florida
AdventHealth Diab Inst
Orlando, Florida
Florida Institute for Clinical Research, LLC
Orlando, Florida
Oviedo Medical Research, LLC
Oviedo, Florida
Endo Res Solutions Inc
Roswell, Georgia
East West Med Res Inst
Honolulu, Hawaii
Cedar-Crosse Research Center
Chicago, Illinois
Iowa Diab & Endo Res Center
West Des Moines, Iowa
Cotton-Oneill Diabetes and End
Topeka, Kansas
L-MARC Research Center
Louisville, Kentucky
Pennington Biom Res Ctr
Baton Rouge, Louisiana
Northern Pines Hlth Ctr, PC
Buckley, Michigan
International Diabetes Center
Minneapolis, Minnesota
StudyMetrix Research LLC
City of Saint Peters, Missouri
Mercury Str Med Grp, PLLC
Butte, Montana
AMC Community Endocrinology
Albany, New York
Southgate Medical Group, LLP
West Seneca, New York
Great Lakes Medical Research
Westfield, New York
PharmQuest Life Sciences LLC
Greensboro, North Carolina
Hillcrest Clinical Research
Simpsonville, South Carolina
Holston Medical Group
Kingsport, Tennessee
Amarillo Med Spec LLP
Amarillo, Texas
Texas Diab & Endo, P.A.
Austin, Texas
Texas Diab & Endo, P.A.
Austin, Texas
Velocity Clinical Res-Dallas
Dallas, Texas
North Texas Endocrine Center
Dallas, Texas
Showing 40 of 179 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.